investing.comOCT 161 min read$ADIL

Adial Pharmaceuticals appoints David Rubenstein as chief scientist

Adial Pharmaceuticals (NASDAQ:ADIL) appointed David Rubenstein, M.D., Ph.D. as Chief Scientist to lead research and development of AT177, a treatment for ulcerative colitis. Rubenstein previously led the FDA approval of tapinarof at Dermavant Sciences. AT177 is expected to begin first-in-human trials in 2027, according to the company.

Original reporting

investing.com

Published Oct 16, 2026, 11:04 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 16, 2026, 11:08 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$ADIL

Bullish

medium confidence

Mentioned

$ADIL

Relevance

5/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$ADILBullishLow

Why it matters

Executive hire could boost investor confidence but lacks immediate catalyst.

Market read

A modest, company-specific development with limited broader market effect.

What to watch

No disclosed timeline for trial results; market may already price in the hire.

Relevance 5/10Novelty 5/10Timing: today

Background

Adial Pharmaceuticals is developing AT177, an oral AhR agonist for ulcerative colitis, after acquiring Azora Therapeutics.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ADILBullishMedium confidence

Context

Adial Pharmaceuticals announced the appointment of David Rubenstein as Chief Scientist, a new executive hire leading its AT177 program.

Expected impact

potential modest upside as investors view the appointment favorably

Evidence & confidence

Executive appointments in biotech can signal progress and attract interest, but impact is limited without accompanying data.

Market effects

Sector

Highlights continued focus on AhR agonist development in ulcerative colitis space.

Regional

Limited to US biotech investors.

Global

Minor, as the news is company-specific.

Counterpoint

What could challenge this read

The appointment may not translate into meaningful clinical progress, limiting stock impact.

Key entities

person
David Rubenstein
New Chief Scientist at Adial Pharmaceuticals.
company
Adial Pharmaceuticals
Biotech firm developing AT177 for ulcerative colitis.

Read at source ← All news

AUG 17

$ADILMed

Adial Posts Q2 2026 Results; Acquisition Of Azora Therapeutics Shifts Focus To UC; Stock Down

Adial Pharmaceuticals (ADIL) reported Q2 2026 results ended June 30, 2026, including a Q2 net loss of $52.0M ($11.25/share) versus $2.0M in Q2 2025. Cash was $28.7M. The company completed the first $32M tranche of a $64M private placement and acquired Azora Therapeutics, adding AT177 for ulcerative colitis. ADIL stock fell to $3.98.

rttnews.com4 min

AUG 17

$ADILLow

ADIAL PHARMACEUTICALS, INC. (ADIL): Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative

SEC EDGAR 8-K2 min

JUN 12

$ADILMedAI 9/10

Adial Acquires Azora With $64 Mln Private Placement; To Advance AT177 For Ulcerative Colitis

Adial Pharmaceuticals said it will acquire Azora Therapeutics and obtain its lead asset AT177 for ulcerative colitis. The deal is paired with a $64 million private placement, including $32 million upfront, issuing pre-funded warrants for 11,780,948 shares at $2.7489. A further $32 million milestone is tied to Phase 1 start. Proceeds will fund AT177 development; proof-of-concept studies are planned for 2027.

rttnews.com4 min

JUN 11

$ADILMed

ADIAL PHARMACEUTICALS, INC. (ADIL): Completion of Acquisition or Disposition of Assets

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029444801ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JUNE 11, BY AND AMONG ADIAL PHARMACEUTICALS, INC., ADIAL FIRST MERGER SUB, INC., ADIAL SECOND MERGER SUB, LLC AND AZORA THERAPEUTICS, INC Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among: Adi

SEC EDGAR 8-K6 min

OCT 24

$CVXLow

Ministry of Petroleum and Mineral Resources and Chevron Announce Positive Results from Nargis-2 Well in the Mediterranean Sea

Chevron and Egypt's Ministry of Petroleum announced positive results from the Nargis-2 gas well in the Mediterranean. The well confirmed extended gas-bearing reservoirs and an additional gas interval, supporting further appraisal and development. Chevron operates the area with partners Eni, Mubadala Energy, and Tharwa Petroleum. The well reached 5,000 meters with 35 meters of net gas pay, indicating potential for further development.

petroleum.gov.eg2 min